



Department of  
**Health**

An Roinn Sláinte

Máinnystrie O Poustie

[www.health-ni.gov.uk](http://www.health-ni.gov.uk)

**For Action:** Assistant Director Integrated Care, Head of Pharmacy and Medicines Management, HSC Board & BSO  
Heads of Pharmacy and Medicines Management of HSC Trusts  
Regulation Quality Improvement Authority

From: Chief Pharmaceutical Officer  
Mrs Cathy Harrison  
Castle Buildings  
Upper Newtownards Road  
Belfast BT4 3SQ

Telephone: 028 90 523219  
Facsimile: 028 90 522335

E-Mail: [cathy.harrison@health-ni.gov.uk](mailto:cathy.harrison@health-ni.gov.uk)

Our Ref: PHC/57/2020  
Date: 3 December 2020

## **DRUG ALERT**

### **CLASS 3 MEDICINES RECALL**

**Action within 5 Days**

**Pharmacy and Wholesaler Level**

Dear Healthcare Professional

**Lupin Healthcare (UK) Limited**

**Simvador 10mg Tablets**  
**Simvador 20mg Tablets**  
**Simvador 40mg Tablets**

**PL 35507/0012**  
**PL 35507/0013**  
**PL 35507/0014**

<b>Product</b>	<b>Batch Number</b>	<b>Expiry Date</b>	<b>Pack Size</b>	<b>First Distributed</b>
Simvador 10mg Tablets	G902211	Jan-22	28's	07/01/2020
Simvador 20mg Tablets	G902283	Jan-22	28's	29/10/2019
Simvador 40mg Tablets	G803251	Feb-21	28's	27/07/2018
Simvador 40mg Tablets	G803252	Feb-21	28's	27/07/2018
Simvador 40mg Tablets	G803253	Feb-21	28's	27/07/2018
Simvador 40mg Tablets	G803254	Feb-21	28's	27/07/2018
Simvador 40mg Tablets	G802355	Feb-21	28's	27/07/2018
Simvador 40mg Tablets	G902245	Jan-22	28's	14/11/2019
Simvador 40mg Tablets	G902242	Jan-22	28's	19/11/2019
Simvador 40mg Tablets	G902243	Jan-22	28's	30/12/2019
Simvador 40mg Tablets	G902241	Jan-22	28's	29/01/2020

Active Pharmaceutical Ingredient: simvastatin

## **Brief description of the problem**

Lupin Healthcare (UK) Limited has informed us that the affected batches above (also distributed by Discovery Pharmaceuticals/Dexcel Pharma Limited) have been packaged with a version of patient information leaflet (PIL) that does not include the most up to date safety information.

There are no concerns with the quality, safety and efficacy of the product. However, these affected batches are being recalled due to concerns around the omission of the safety information. The information missing from the PILs are as below:

### Section 2 What you need to know before you take Simvador:

Do not take Simvador if you:

- If you are taking one or more than one of the following drugs at the same time:
  - **Cobicistat**
  - **Lomitapide (used to treat a serious and rare genetic cholesterol condition)**

### Section 2 Warnings and Precautions:

Tell your doctor:

- **If you are Asian, because a different dose may be applicable to you**

### Section 2 Other medicines and Simvador:

Do not take Simvastatin and tell your doctor if you are taking:

- **Elbasvir or grazoprevir (medicines for Hepatitis C virus infection)**
- **medicines with the active ingredient cobicistat**
- **amiodarone (used to treat an irregular heartbeat)**
- **lomitapide (used to treat a serious and rare genetic cholesterol condition)**
- **daptomycin (a drug used to treat complicated skin and skin structure infections and bacteraemia). It is possible that side effects affecting the muscles may be higher when this medicine is taken during treatment with simvastatin. Your doctor may decide that you stop taking simvastatin for a while**

### Section 3 How to take Simvador

**If you stop taking Simvador, talk to your doctor or pharmacist because your cholesterol may rise again. If you have any further questions on the use of this product, ask your doctor or pharmacist**

### Section 4 Possible side effects

The following rare serious side effects were reported:

- **Hypersensitivity (allergic) reactions including:**
- **Swelling of the face, tongue and throat which may cause difficulty in breathing (angioedema)**
- **Severe muscle pain usually in the shoulders and hips**
- **Rash with weakness of limbs and neck muscles**
- **Pain or inflammation of the joints**
- **Inflammation of the blood vessels (vasculitis)**
- **Unusual bruising, skin eruptions and swelling (dermatomyositis), hives, skin sensitivity to the sun, fever, flushing**
- **Shortness of breath (dyspnoea) and feeling unwell**
- **Lupus-like disease picture (including rash, joint disorders and effects on blood cells)**

The following very rare serious side effect was reported:

- **A serious allergic reaction which causes difficulty in breathing or dizziness (anaphylaxis)**

The following side effects have also been reported rarely:

- **Trouble sleeping (very rare)**

The following side effects have also been reported but the frequency cannot be estimated from available information (frequency unknown)

- Inflammation of the lungs causing breathing problems including persistent cough and/or shortness of breath or **fever**

**Advice for healthcare professionals**

Stop supplying the above batches immediately. Quarantine all stock and return it to your supplier using your supplier's approved process.

As a general reminder, patients who experience side effects from taking any medicines should be encouraged to report a suspected problem or incident via the [Yellow Card scheme](#) and seek medical advice accordingly.

**Further Information**

For stock control enquiries please contact +44 (0) 1565 751 378 Option 2 or [information@lupin.com](mailto:information@lupin.com)


For more information or medical information enquiries please contact +44 (0) 1565 751 378 Option 1 or Pharmacovigilance Department at [EU-PV@lupin.com](mailto:EU-PV@lupin.com)

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this notice

RQIA should bring this information to the attention of private hospitals/clinics registered with them and any other relevant care facilities

The Business Services Organisation is asked to bring this information to the attention of Community Pharmacists and General Medical Practitioners directly.

Yours sincerely



Mrs Cathy Harrison  
Chief Pharmaceutical Officer